

Product Name:
Issued:

Levothyroxine Sodium
Jun-16-2014



SAFETY DATA SHEET

Section 1. Identification of the substance/mixture and of the company/undertaking

1.1 Product Identifier

Product Name: Levothyroxine Sodium

Synonyms: Sodium Levothyroxine: Levothyroxine Sodium USP: Sodium Levothyroxine hydrate: L-Thyroxine Sodium: Sodium Thyroxine: Levothyroxine Sodium Stage 7: Levothyroxine Sodium Stage 6 Intermediate: Stage 6 Intermediate: Levothyroxine Sodium, EP: Levothyroxine Sodium, USP, Milled, Domestic: Levothyroxine Sodium, USP, Milled, International: Stage 6: Stage 7: Levothyroxine Sodium (Stage 6): Levothyroxine Sodium (Stage 7): Levotiroxina sodica

Drug Code Number: 259630: 224245: 22534: 46848: 22534: 79420: 44461: 10056539: 10055875

1.2 Relevant identified uses of the substance or mixture and uses advised against

Recommended use: Pharmaceuticals

1.3 Details of the supplier of the safety data sheet

Supplier: AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064
USA
+1-847-932-7900

Customer Service Telephone: 1-800-255-5162 (US and Canada only)
+1-847-937-7433

E-mail Address: AbbVie.SDS@abbvie.com

1.4 Emergency telephone number

Emergency Telephone: CHEMTREC: 1(800) 424-9300 (in USA and Canada)
or +1-703-527-3887 (international)

Section 2. Hazards identification

2.1 Classification of the substance or mixture

Regulation (EC) No 1272/2008

Reproductive toxicity Category 2

Specific target organ systemic toxicity (repeated exposure) Category 1

Classification according to EU Directives 67/548/EEC or 1999/45/EC

Indication of danger: T - Toxic

Product Name: Levothyroxine Sodium
Issued: Jun-16-2014

Section 2. Hazards identification

Risk Phrases: R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed
R63 - Possible risk of harm to the unborn child

2.2 Label elements



Signal Word: Danger

Hazard Statements: H361 - Suspected of damaging fertility or the unborn child
H372 - Causes damage to organs through prolonged or repeated exposure

P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P264 - Wash face, hands and any exposed skin thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P314 - Get medical advice/attention if you feel unwell
P501 - Dispose of contents/container to an approved waste disposal plant

2.3 Other hazards

Not determined

Section 3. Composition/information on ingredients

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Levothyroxine Sodium 55-03-8	100	Present	T, R48/22; R63	STOT RE 1 (H372) Repr. 2 (H361)	No data available

For the full text of the R-phrases mentioned in this Section, see Section 16
For the full text of the H-Statements mentioned in this Section, see Section 16

Section 4. First aid measures

4.1 Description of first aid measures

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Product Name: **Levothyroxine Sodium**
Issued: **Jun-16-2014**

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Protection of First-aiders: Use personal protective equipment

4.2 Most important symptoms and effects, both acute and delayed

Signs and Symptoms: Reported to cause the following: headaches, fast heart rate, increased blood pressure, diarrhea, nausea, gastrointestinal upset, sweating, low blood sugar. Clinical overdose may result in the following: abnormal thyroid function.

Medical Conditions Aggravated by Exposure: Data suggest any pre-existing ailments in the following organs: cardiovascular system, gastrointestinal system, thyroid. Hypersensitivity to the material and/or similar materials. Concurrent use of medications.

4.3 Indication of any immediate medical attention and special treatment needed

Notes To Physician: Monitor cardiovascular system function. Monitor thyroid function, as necessary.

Section 5. Firefighting measures

5.1 Extinguishing Media

Suitable Extinguishing Media: Use extinguishing agent suitable for type of surrounding fire

Unsuitable Extinguishing Media: Not determined

5.2 Special hazards arising from the substance or mixture

Special Exposure Hazards: Not determined

5.3 Advice for firefighters

Protective Equipment and Precautions for Firefighters: As in any fire, wear self-contained breathing apparatus and full protective gear

Section 6. Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal Precautions: For personal protection see section 8

6.2. Environmental precautions

Environmental Precautions: Contain material and prevent release to waterways or soil.

6.3. Methods and material for containment and cleaning up

Methods for Cleaning Up: Recover product and place in an appropriate container for disposal.

Product Name: Levothyroxine Sodium
Issued: Jun-16-2014

6.4. Reference to other sections

Refer to Sections 8, 12, and 13 for further information.

Section 7. Handling and storage

7.1. Precautions for safe handling

Avoid contact with skin, eyes and clothing. Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store according to label instructions.

7.3. Specific end use(s)

Recommended use: Pharmaceuticals

Section 8. Exposure controls/personal protection

8.1. Control parameters

Exposure limits:

Chemical Name	Employee Exposure Limit	Skin Notation
Levothyroxine Sodium 55-03-8	3 mcg/m ³ TWA	None

8.2. Exposure controls

Engineering Controls: Use inside a hood, glovebox or process enclosure.

Respiratory Protection: An approved respirator (i.e. NIOSH, EN, etc.) should be worn when exposures are expected to exceed the applicable limits.

Eyes: Wear eye protection appropriate to handling activities.

Gloves: Impervious gloves.

Other PPE Data: Wear appropriate body coverings if contact may occur.

Environmental Exposure Controls: Not determined

Section 9. Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance: White to light brown Solid

Odor: Odorless.

Odor Threshold: Not determined

pH: 8.35-9.35 as a saturated aqueous solution.

Boiling Pt. @ 760 mm Hg (°C): Not determined.

Melting/Freezing Point (°C): Not determined

Product Name:	Levothyroxine Sodium
Issued:	Jun-16-2014
Flash Point (°C):	Not determined.
Evaporation Rate at 20°C:	Not determined.
Flammability (Solid):	Not determined.
Lower Explosive Limit:	Not determined.
Upper Explosive Limit:	Not determined.
Vapor Pressure (mm Hg):	Not determined.
Vapor Density (Air = 1):	Not determined.
Specific Gravity:	2.38 g/cm ³
Solubility(ies):	Soluble in: alcohol. Slightly soluble in: water, chloroform, ether.
Partition coefficient: n-octanol/water	Not determined.
Autoignition Temp. (°C):	Not determined.
Decomposition temperature (°C):	Not determined.
Viscosity (centipoise):	Not determined.
Explosion Severity:	Not determined.
Oxidizer Properties:	Not determined.

9.2. Other information

Not determined

Section 10. Stability and reactivity

10.1. Reactivity

Not determined

10.2. Chemical stability

Stable under normal conditions

10.3. Possibility of hazardous reactions

Hazardous reactions: Not determined.

10.4. Conditions to avoid

Not determined.

10.5 Incompatible materials

Strong bases, Strong acids

10.6 Hazardous decomposition products

Carbon oxides, Nitrogen oxides (NO_x), Hydrogen iodide

Section 11. Toxicological information

11.1. Information on toxicological effects

Routes of Exposure:

Oral:	Yes
Dermal:	Yes
Inhalation:	Yes

Product Name: **Levothyroxine Sodium**
Issued: **Jun-16-2014**

Acute Toxicity - Oral: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Levothyroxine Sodium 55-03-8	ALD =	2400	mg/kg	Dogs

Acute Toxicity - Dermal: Not determined.

Acute Toxicity - Inhalation: Not determined.

Other Toxicology Data: Data for component (s) given below:

Chemical Name	Test Type	Value	Units	Species	Comments
Levothyroxine Sodium 55-03-8	LD50 (ip) =	20	mg/kg	Rats	None.
	LD50 (sc) =	50	mg/kg		

Corrosivity: Not determined.

Dermal Irritation: Not determined.

Eye Irritation: Not determined.

Sensitization: Not determined.

Toxicokinetics/Metabolism: Not determined.

Target Organ Effects: Data for component (s) given below.

Chemical Name	Target Organs:	Species	Dosage	Units	Route	Duration
Levothyroxine Sodium 55-03-8	Thyroid Gastrointestinal Tract Cardiovascular System Kidney Fetus	Rats Rabbits	200	mcg/kg	Oral	Variable exposure periods

Reproductive Effects: In animals adverse reproductive effects include: fetal abnormalities, maternal toxicity, reduced fetal growth, fetal toxicity.
Data for component (s) given below.

Chemical Name	Species	Dosage	Units	Route	Duration
Levothyroxine Sodium 55-03-8	Rats Rabbits	120	mcg/kg	Oral	During Gestation

Carcinogenicity: Not determined.

Mutagenicity: Not determined.

Aspiration hazard: Not determined

Notes:

1. ALD: Approximate lethal dosage
2. LC50: Concentration in air that produces 50% mortality
3. LD50: Oral or dermal dosage that produces 50% mortality

Section 12. Ecological information

12.1. Toxicity

Product Name: Levothyroxine Sodium
Issued: Jun-16-2014

Not determined.

12.2. Persistence and degradability

Not determined.

12.3. Bioaccumulative potential

Not determined

12.4. Mobility in soil

Not determined.

12.5. Results of PBT or vPvB assessment

Chemical safety report is not required for this substance/product.

12.6. Other adverse effects

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

Notes:

1. EC50: Concentration in water that produces 50% mortality in *Daphnia* sp.
2. LC50: Concentration in water that produces 50% mortality in fish.
3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

Section 13. Disposal considerations

13.1 Waste treatment methods

Waste Disposal Methods: Disposal should be made in accordance with country, federal, state and local regulations.

Section 14. Transport information

ADR, DOT, ICAO/IATA, IMDG/IMO

Status: Not regulated

- 14.1. UN Number:** Not applicable
14.2. Proper shipping name: Not applicable
14.3. Hazard class: Not applicable
14.4. Packing group: Not applicable
14.5. Environmental hazard: Not applicable
14.6. Special Provisions: Not applicable
14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code: Not applicable

Section 15. Regulatory Information

Product Name: Levothyroxine Sodium
Issued: Jun-16-2014

Section 15. Regulatory Information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Levothyroxine Sodium 55-03-8	Present	X	-	X	-

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Levothyroxine Sodium 55-03-8	Present	Present	-	X	-	

Legend

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

ENCS - Japan Existing and New Chemical Substances

ISHL - Japan Industrial Safety and Health Law

IECSC - China Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

Carcinogenicity Rating:

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Levothyroxine Sodium	100	Not Listed	Not Listed	Not Listed

SARA 313 Information

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA EHS RQ (lbs):	SARA EHS TPQ (lbs):
Levothyroxine Sodium	100	No	Not Applicable	Not applicable

Immediate Health: Yes

Delayed Health: No

Fire: No

Sudden Pressure: No

Reactivity: No

RCRA Status: Not determined.

Proposition 65 Status: Does not contain chemicals known to the state of California to cause cancer or reproductive harm.

WHMIS Hazard Class: Not determined.

NFPA Rating:

Health: 1

Fire: 1

Reactivity: 0

Product Name:
Issued:

Levothyroxine Sodium
Jun-16-2014

Notes:

1. SARA = Superfund Amendments and the Reauthorization Act.
2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
4. TSCA = Toxic Substances Control Act.
5. EC = European Community.
6. WHMIS = Canadian Workplace Hazardous Materials Information System.
7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

15.2. Chemical safety assessment

Chemical safety assessment has not been conducted on the substance/product.

Section 16. Other information

Risk Phrases: R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed, R63 - Possible risk of harm to the unborn child

Full text of H-Statements referred to under sections 2 and 3

H361 - Suspected of damaging fertility or the unborn child, H372 - Causes damage to organs through prolonged or repeated exposure

Document Authored By: Occupational and Environmental Toxicology

Issued: Jun-16-2014

Supersedes the SDS dated: Aug-03-2011

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.